After a combination of favezelimab (Anti-LAG3) and pembrolizumab demonstrated safety and robust efficacy in the PD-L1 combined positive score (CPS) ≥ 1 MSS mCRC, a phase 3 trial is comparing it to SOC in PD-L1 positive CRC (NCT05064059) (Table 1) [129]. Here, LAG3 is linked to colorectal carcinoma.